Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-75.00M |
| EBITDA | $-1.07B |
| Operating Margin | 0.00% |
| Return on Equity | -30.50% |
| Return on Assets | -20.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $20.76 |
| Price-to-Book | 2.28 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -14.43 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $144.40M |
| Float | $131.96M |
| % Insiders | 0.53% |
| % Institutions | 114.57% |
Volatility is currently contracting